CD274 and non-small cell lung carcinoma: Supporting this notion toward a biomarker-informed management of ICI treatments, a phase 2 HUDSON study attempted a biomarker-driven combinatorial approach for advanced NSCLC patients with primary and acquired resistance to anti-PD(L)1 treatments.